Zacks Investment Research
28 Sept 2026, 22:51 UTC · 4h ago
Verdict
Headline leans bearish. We score RXRX +0.20 across three claims.
Score contradicts the headline.
Leans bearish
From its wording — no explicit rating
+0.20slightly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
The Zacks Consensus EPS estimate for Recursion Pharmaceuticals has decreased by 2.82% over the last month.
Priced inanalysis of trends over the past month
So whatThe decline in analyst expectations suggests a downward trend in near-term EPS estimates ahead of the next print.
More negative than 76% of claims this week
Recursion is expected to report a quarterly EPS of -$0.24, an improvement of 33.33% over the prior-year quarter.
Continue reading
5 related stories
More positive than 57% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Priced inconsensus estimate for upcoming release
So whatBeating this -$0.24 estimate would signal a faster reduction in the company's quarterly cash burn.
More positive than 54% of claims this week
Quarterly revenue is forecasted at $8.42 million, representing a growth of 62.57% year-over-year.
Priced inconsensus estimate for upcoming release
So whatThe high growth rate helps offset the projected full-year revenue decline of 46.01%.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 57% of ticker scores this week
The company shows strong monthly gains and expects significant revenue growth and improved EPS for the upcoming quarter.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
4h ago
—
RXRX hasn't traded since this ran. Last close $3.70 (Sep 28); the reaction starts at the next open.
RXRX chart →
